Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Study sponsor: Sutro Biopharma, Inc. · STRO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-01-21Actual
Enrollment · participants1Actual
Source updated2026-10-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.